Infertility Treatment Market Overview
Infertility Treatment Market size was valued at USD 2,551.30 million in 2022 and is estimated to reach at a compound annual growth rate (CAGR) of 8.10% over the forecast period 2024-2031.
Infertility is a condition where a person is unable to reproduce by natural means. Treatment of infertility depends on the cause of the condition. The various causes of infertility include sexually transmitted infections, genetic problems, DNA damage due to smoking, diabetes mellitus, and toxins such as chemical dusts, glues and pesticides.
Market Scope
| Metrics | Details |
| Market CAGR | 8.10% |
| Segments Covered | By Procedure, By Product, By Patient Type, By End-User, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
To know more insights into the Market, Get Our Sample Brochure
Market Dynamics
The global infertility treatment market growth is driven by the declining fertility rate, rising fertility clinics worldwide, technological advancements, high prevalence of lifestyle disorders, and growing public awareness about infertility and the available treatment options.
Declining fertility rate is expected to drive the growth in the forecast period
The fertility rate worldwide is declining steadily owing to various factors, such as the growing trend of late marriages and increasing age-related infertility. Global fertility rates are projected to decline to 2.4 children per woman by 2030 and 2.2 children per woman by 2050. This declining fertility rate has led to a significant increase in the demand for infertility treatment products that determine the fertility window in males and females. Smoking is one of the major reasons for declining fertility rates and the high prevalence of lifestyle disorders. According to the Center for Disease Control & Prevention (CDC), smoking kills more than 480,000 people every year in the U.S. Smoking reduces fertility in female oocytes and male sperm. As the World Health Organization (WHO) reports, tobacco kills more than 7 million people worldwide every year. Thus, the various disorders caused by smoking and the decline in the fertility rate are driving the growth of the infertility treatment market.
High costs associated with assisted reproductive technology in developed markets
Along with fertility surgeries, thousands of cycles of ART procedures such as in vitro fertilization (IVF) are performed every year globally. The cost of IVF treatment varies from country to country due to the lack of reimbursement policies. A lack of insurance coverage and the poor reimbursement scenario in some parts of the world are limiting the growth of this market.
COVID-19 Impact Analysis
The coronavirus pandemic is currently presenting many challenges to clinical healthcare providers and patients across the globe. Logistical issues, managing patients with the disease, prioritizing patients with comorbidities and pre-existing conditions, and protecting public & hospital frontline workers from exposure to the COVID-19 infection are the major challenges healthcare systems face across the globe. One in six reproductive-aged couples experiences infertility, and many turn to treatments such as intrauterine insemination (IUI) and in vitro fertilization (IVF), which require in-person appointments to complete. In India, 30 lakh people seek infertility treatment every year, but only 5 lakhs undergo IVF/intrauterine insemination (IUI) procedures. During the COVID-19 pandemic, a 90% drop was observed in the number of people undergoing IVF cycles. The spread of COVID-19 has not only impacted fertility clinics owing to the cancellation of IVF treatments but has also impacted fertility decisions among couples who were opting for IVF treatment before the pandemic.
Segment Analysis
The fertility centers segment is expected to hold the largest share in this market segment
The rising government initiatives to establish fertility clinics, initiatives taken by large international healthcare providers to establish fertility centers, and the increasing popularity of IVF & ICSI treatment globally. Also, fertility centers would be rising upwards due to the rising importance of infertility treatment over the past years. For instance, according to the IVF-Worldwide information, the number of fertility clinics in the USA is around 360. Fertility clinics are better equipped to deal with infertility issues. Discounts offered by the clinics and grants also work to support the center’s growth better.
Geographical Share
Asia-Pacific region holds the largest market share of the global infertility treatment market
The Asia-Pacific dominates the infertility treatment market. Significant rise in medical tourism, increase in the awareness of the availability of infertility treatment procedures, growing fertility centers in the region, rising healthcare expenditures, increasing rate of infertility in the region, initiatives by the government to increase the accessibility of infertility treatment in the emerging nations and the emergence of top cryobanks companies from the Indian market. For instance, Cryobanks’ importance in the market is sustained by the international players functioning in this domain. Cryoviva India is one such player providing high-quality services for this market.
Competitive Landscape
The global infertility treatment market is highly competitive with the presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include CooperSurgical Inc, Vitrolife, FUJIFILM Irvine Scientific, Inc, Genea Limited, IVFtech ApS, Kitazato Corporation, Rocket Medical plc, Gynemedia, Boston IVF, Aspire Fertility. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the calcium channel blocker globally. For instance, on June 19, 2019, Thermo Fisher Scientific got entered into a global research collaboration with Predictive Laboratories, a wholly-owned subsidiary of Predictive Technology Group, Inc., focused on studying the genetic factors underlying infertility in women. The work will utilize Thermo Fisher's various offerings for reproductive health, including Applied Biosystems CarrierScan Assay, Ion ReproSeq PGS Assay, CytoScan Dx Assay, and Ion AmpliSeq Exome RDY for whole-exome sequencing.
Key Companies to Watch
CooperSurgical Inc
Overview: Cooper Companies operates through two business units, CooperVision (CVI) and CooperSurgical (CSI). The company offers a wide range of products and services focused on women’s health, fertility, and diagnostics through its CooperSurgical business segment. This business unit markets its products under various brand names, such as ORIGIO (provides in vitro fertilization (IVF) products), Reprogenetics (provides genetic testing solutions), and LifeGlobal (provides media products as well as IVF laboratory air filtration products). By offering a broad range of innovative technologies and services to clinicians and patients worldwide, the company aims to further strengthen its position in the market by pursuing the strategy of acquisitions.
Product Portfolio: It includes products like ART IVF devices.
VitriGuard Carrier: VitriGuard is a vitrification carrier for all stages from human oocytes to blastocysts. It works with all media kits.
Key Developments: In May 2016, Cooper Companies, Inc. CooperSurgical had acquired the commercial assets of Recombine Inc., a clinical genetic testing company specializing in carrier screening. The acquisition was an exceptional fit for CooperSurgical as it adds the premier carrier screening test sold within the IVF marketplace to the existing IVF genetic testing platform.
